"Express Mail" mailing label number	
Date of Deposit May 02, 2006	
I hereby certify that this paper or fee is being deposited with the United States Postal Servi	ice "Express Mail Post Office to
Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the	ne Commissioner for Patents, P.O.
Box 1450, Alexandria, VA 22313-1450.	
Printed Name Signature	ones

PATENT APPLICATION IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Applicant: Robert Peter GAJEWSKI

Group Art Unit:

Serial No.:

Examiner: Conf No.:

Application Date: Filed Herewith

For: Docket No.:

VITAMIN D RECEPTOR MODULATORS X-15439

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provides a copy of each of the listed non patent documents for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,

James B. Myers Autorney for Applicants

Registration No. 42,021 Phone: 317-276-0755

Eli Lilly and Company Patent Division P.O. Box 6288

Indianapolis, Indiana 46206-6288

Man 2006

IAP20 ROS L. V. 1770 02 MAY 2006

Sheet 1 of 2

FORM PTO 1449 (modified)	Atty. Docket No. X-15439	Serial/9577967
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	First Applicant Robert Peter GAJEWSKI	
	Application Date US Nat'l Entry (if applicable)	Group Art Unit

U.S. PA	TENT	DOCUMENTS			
Examiner Initials*	Cite No. 1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
	AA	US 6,218,430 B1	04-17-2001	Allegretto, E. et al	
	AB	US			

Examiner		Date Considered	
Signature			
*EYAMINER	Initial if reference considered, whether or not citation is in conformance with MPEP 609.	Draw line through citation if no	t in conformance and not considered. Include many of

¹ Applicant's unique clarito designation number (options); ² See Kinds Codes of USPTO Paren Documents as www.upetn.ppg on MPEP 901.04. ³ Exerc Office that issued the document, by the row-lear on CHIPO STANDART ST.3. ⁴ For Injuriese partner document, the indication of the year of the region of the Euperon usual perceduc the serial number of the passes document. Next of document by the appropriate symbols as indication does document used WPIPO Standard ST.3. (16 yousble ⁴ Applicant is partner extent with the IT Epitish Instantion is standard.)

this form with next communication to applicant.

Deleted Hours Statement: This form is estimated to take 2.0 hours so complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Oil, 1865. U.S. Patent and Toffeen, Washington, DC 20231. DO

NOT SEND PEES OR COMPLETED ORNOWS TOTHIS ADDRESS. SEND TO. Commissioner for Passers, P.O. Box 1400. Alexandrin, VA 22313-1450.



02 MAY 2006

Sheet 2 of 2

FORM PTO 1449 (modified)	Atty. Docket No. X-15439	Serial No. 77 9 6 7
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	First Applicant Robert Peter GAJEWSKI	. '
	Application Date US Nat'l Entry (if applicable)	Group Art Unit

xaminer Initials*	Citc No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher,	. т6
	-	city and/or country where published.	
	CA	Masahiko Inouye, Toshiyuki Miyake, Masaru Furusyo, Hiroyuki Nakazumi:	
		"Molecular recognition of beta-Ribofuranosides by synthetic	l
		polypyridine_macrocyclic receptors" J.Am. Chem. Soc. Vol. 117, 1995, pages 12416- 12425, XP001206518.	
	CB	Ping Huang, John Ramphal, James Wei, Congxin Liang, Bahija Jallal, Gerald	
		McMahon and Cho Tang: "Structure-based design and discovery of novel inhibitors of protein tyrosine phosphatases" Bioorganic & Medicinal Chemistry, vol. 11, 2003, pages 1835-1849, XP001206517.	
	CC	NAGPAL, S. et al. "Vitamin D Analogs: Mechanism of Action of Therapeutic	
	-	Applications", Curr. Med. Chem. 2001, 1661-1679, vol.8.	
	CD	BOEHM, M., "Novel Nonsecosteroidal Vitamin D Mimics Exert VDR-modulating Activities" Chemistry & Biology, 1999, 265-275, vol 6(5).	
	CE	BOUILLON R., et al. Endocrine Rev. 1995, 200-257, vol. 16,	
	CF	SWANN et al. "Rational Design of Vitamin D3 Analogues Which Selectively Restore	E
		Activity to a Vitamin D Receptor Mutant Associated with Rickets" Org. Lett. 2002, p1863-3866 vol. 4.	
	CG	SWANN et al. "Structure-Based Design of Selective Agonists for a Rickets-	
		Associated Mutant of the Vitamin D Receptor" J. Am. Chem. Soc. 2002 13795- 13805, vol. 124.	

Examiner	/Karl Puttlitz/	Date Considered	03/16/2009

AMINER: Instal if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy

Inguistres' unsigne classion designation number (systems). ² Ger Kieds Codes of USPTO Pieter Documents as <u>were useful</u>, <u>never NEPF-901 No.</u> ² fairer forfire that issued the documents, by the vale test of Cell NIPO Standard ST.3. ² For Inguistres parter document. ² In the indicated of the year of the religion of the Empower must percode the serial number of the patter document. ² Only of documents by the appropriate symbols as indicated on the document used well/OS standard ST.1. 61 passible. ² Application is up place a check must be not English Stangard Translation is unached. ² Application is up place a check must be with English Stangard Translation is unached. ² Application of the Empower of the Standard ST.1. 61 passible. ² Application is up place a check must be with English Stangard Translation is unached. ² Application is unached